Lisinopril in Children Under 12: Off-Label Use, Dosing, and Safety

Why Lisinopril Is Used Off-Label in Children Under 12

Lisinopril's FDA label covers hypertension in patients aged 6 to 16 years. Below age 6, and for non-hypertensive diagnoses at any pediatric age, clinicians rely on off-label evidence. The pharmacological rationale is well-established: ACE inhibitors reduce angiotensin II production, lower intraglomerular pressure, and decrease aldosterone secretion, effects that benefit several pediatric conditions beyond essential hypertension. [1][2]

The Regulatory Gap Below Age 6

The FDA's 1998 Pediatric Rule and subsequent Pediatric Research Equity Act required sponsors to study drugs in children, but lisinopril's pediatric label stops at age 6 because trial enrollment of very young children presented logistical and ethical barriers. [3] A manufacturer-sponsored pharmacokinetic study published in the Journal of Clinical Pharmacology showed that children aged 6 months to 5 years achieved comparable AUC exposures to older children when dosed at 0.1 mg/kg, supporting cautious extrapolation to younger cohorts. [4]

Conditions Driving Off-Label Prescribing

The three most common off-label indications in children under 6 or under 12 with non-hypertensive diagnoses are:

1. Proteinuric chronic kidney disease (CKD): Nephrotic and nephritic syndromes, focal segmental glomerulosclerosis (FSGS), and Alport syndrome all generate proteinuria that ACE inhibitors reduce through hemodynamic and non-hemodynamic mechanisms. [5]
2. Dilated cardiomyopathy (DCM) and heart failure: Pediatric DCM carries a 5-year transplant-free survival below 50% without medical therapy; ACE inhibitors are a cornerstone of heart failure management in children. [6]
3. Post-cardiac surgery hypertension and ventricular remodeling: Children after coarctation repair or single-ventricle palliation frequently receive ACE inhibitors to reduce afterload. [7]

Pharmacokinetics in Young Children

Lisinopril is not hepatically metabolized. It is absorbed intact from the gastrointestinal tract, circulates unbound to plasma proteins, and is eliminated entirely by the kidneys. This profile simplifies drug interactions but makes renal function the dominant pharmacokinetic variable. [8]

Age-Related Absorption Differences

Oral bioavailability in adults is approximately 25%, with considerable interindividual variation. Data from a pediatric PK study (N=52, ages 6 months to 15 years) showed that children under 6 years exhibited slightly higher weight-normalized clearance than older children, suggesting younger children may need proportionally higher per-kilogram doses to reach equivalent plasma levels. [4] The study reported a mean half-life of 11.5 hours across all age groups, consistent with once-daily dosing.

Renal Elimination and Dose Adjustment

Because lisinopril clearance tracks glomerular filtration rate (GFR) directly, any child with CKD stage 3 or worse (eGFR <30 mL/min/1.73 m²) requires dose reduction and more frequent electrolyte monitoring. [9] The FDA label for adults recommends starting at 2.5 mg in patients with creatinine clearance <30 mL/min; this principle applies to pediatric CKD patients as well, scaled by weight. [1]

Dosing Protocols for Children Under 12

Weight-based dosing is standard. The accepted starting point is 0.07 mg/kg once daily, with up-titration every 2 to 4 weeks based on blood pressure response, proteinuria reduction, and tolerability. [10]

Standard Hypertension Dosing

• Starting dose: 0.07 mg/kg/day (maximum 5 mg for the first dose regardless of weight)
• Titration: Increase by 0.07 mg/kg/day increments every 2 weeks
• Maximum: 0.6 mg/kg/day or 40 mg/day, whichever is lower
• Frequency: Once daily; the long half-life supports single daily administration in most children [1]

The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents (NHBPEP, NIH Publication 05-5267) recommends ACE inhibitors as preferred first-line agents in children with hypertension complicated by CKD or diabetes, specifically noting that weight-based dosing and close renal monitoring are required. [10]

Proteinuria Reduction Dosing

When the target is proteinuria reduction rather than blood pressure normalization, some pediatric nephrologists titrate to higher per-kilogram doses, accepting mild hypotension if the urine protein-to-creatinine ratio falls below 0.2. A retrospective cohort study in children with FSGS (N=47, mean age 7.3 years) found that doses above 0.3 mg/kg/day produced significantly greater proteinuria reduction (mean 58% decrease from baseline) compared with doses at or below 0.1 mg/kg/day (mean 22% decrease), though systolic blood pressure fell by an average of 8 mmHg in the higher-dose group. [5]

Heart Failure Dosing

Pediatric heart failure guidelines from the American Heart Association recommend starting ACE inhibitors at 0.05 to 0.1 mg/kg/day and titrating toward a target of 0.3 to 0.5 mg/kg/day as tolerated, with dose increases no more frequently than weekly in the inpatient setting. [6] A prospective observational study of 63 children with DCM (ages 2 months to 14 years) found that sustained ACE inhibitor therapy for at least 12 months was associated with significant improvement in left ventricular end-diastolic dimension z-score (mean change: -1.8, P<0.001). [11]

Formulation Challenges in Young Pediatric Patients

Lisinopril is commercially available only as tablets (2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg) and, in some markets, as a 1 mg/mL oral solution (Qbrelis, FDA-approved 2016) for patients 6 years and older. [12] Children under 6, or those unable to swallow tablets, typically require compounded oral suspensions.

Compounding Considerations

Compounding pharmacies commonly prepare a 1 mg/mL suspension using crushed tablets mixed with a 1:1 mixture of Ora-Plus and Ora-Sweet or simple syrup. A stability study demonstrated that such compounded suspensions remain within 90% to 110% of labeled potency for up to 4 weeks when refrigerated. [13] Prescribers should specify the concentration and vehicle explicitly on the prescription to avoid dosing errors.

Qbrelis in the 6-to-11-Year Range

Qbrelis (lisinopril oral solution, 1 mg/mL) received FDA approval for hypertension in patients 6 years and older. [12] Its use in the 6-to-11-year range is within label for hypertension but remains off-label for heart failure and CKD-proteinuria reduction at any pediatric age. Clinicians using Qbrelis for off-label indications in this subgroup should document the indication and the evidence base supporting use.

Safety Profile and Monitoring

Adverse events in pediatric patients mirror the adult profile but with some age-specific nuances. The most concerning acute effects are hypotension, hyperkalemia, and acute kidney injury (AKI). [14]

Hypotension

First-dose hypotension is more pronounced in volume-depleted children, those on concurrent diuretics, and those with baseline low blood pressure from cardiac dysfunction. A pharmacovigilance review of FDA Adverse Event Reporting System (FAERS) data identified hypotension as the most frequently reported adverse event for lisinopril in patients under 12 years, accounting for 31% of pediatric reports over a 10-year period. [15]

Hyperkalemia

ACE inhibitor-induced hyperkalemia results from reduced aldosterone secretion. Children with CKD, those receiving potassium-sparing diuretics, or those on potassium supplementation are at highest risk. Serum potassium should be checked within 1 to 2 weeks of any dose change. A potassium level above 5.5 mEq/L warrants dose reduction or temporary discontinuation. [9]

Acute Kidney Injury

A transient rise in serum creatinine of up to 30% from baseline is expected and acceptable when starting an ACE inhibitor in children with CKD, reflecting the intended reduction in intraglomerular pressure. Rises exceeding 30% or accompanied by oliguria should prompt cessation and evaluation for renal artery stenosis. [5][9]

Cough and Angioedema

ACE inhibitor-induced cough (bradykinin-mediated) occurs in approximately 5% to 15% of patients across all ages. [8] Angioedema is rare but potentially life-threatening; the estimated incidence is 0.1% to 0.7% in general ACE inhibitor users. [14] Children of Black ancestry face a 3- to 5-fold higher angioedema risk compared with white patients, a pharmacogenomic difference well-documented in adult trials that almost certainly extends to pediatric populations. [2]

Monitoring Schedule

The following schedule reflects consensus from pediatric nephrology and cardiology practice guidelines:

| Timepoint | Tests Required | |---|---| | Baseline | BMP (Cr, BUN, K), CBC, urinalysis with protein, BP | | 1-2 weeks after initiation | BMP, BP | | After each dose increase | BMP within 1-2 weeks, BP | | Every 3 months (stable dose) | BMP, urinalysis with protein | | Annually | Full metabolic panel, renal ultrasound (CKD patients) |

Clinical Evidence Supporting Off-Label Use

The evidence base for lisinopril specifically (as opposed to ACE inhibitors as a class) in young children is limited but growing. Most trials enrolled children aged 6 to 18 years; extrapolation below age 6 relies on pharmacokinetic data, case series, and mechanistic reasoning.

Hypertension Trials in Younger Children

A double-blind, dose-ranging study of lisinopril in 115 pediatric hypertensive patients (ages 6 to 16 years) showed dose-dependent blood pressure reduction: the 0.1 mg/kg/day group achieved a mean trough sitting systolic BP reduction of 3.8 mmHg, while the 0.6 mg/kg/day group achieved 11.1 mmHg, both versus 0.9 mmHg for placebo. [1] Sub-analysis of the 6-to-9-year cohort (N=31) showed similar dose-response relationships, providing indirect support for use down to age 6.

CKD and Proteinuria Evidence

The ESCAPE trial (N=385, ages 3 to 18 years) randomized children with CKD stages 2 to 4 to either intensified blood pressure control (target mean arterial pressure below the 50th percentile for age) or conventional control, using ramipril as the primary ACE inhibitor. [16] After a median follow-up of 5 years, the intensified group showed a 35% reduction in the risk of GFR decline below 50% of baseline (P<0.001). While ramipril rather than lisinopril was used, the trial established the principle of ACE inhibitor use in young children with CKD, and the ESCAPE cohort included children as young as 3 years.

The Kidney Disease Improving Global Outcomes (KDIGO) 2021 CKD guidelines state: "We recommend using an ACE inhibitor or ARB in children with CKD who have proteinuria greater than 1 g/day, regardless of blood pressure." [17] This recommendation explicitly covers children of all ages.

Heart Failure and Cardiomyopathy Data

The PCMR (Pediatric Cardiomyopathy Registry) analyzed 929 children with DCM and found that ACE inhibitor use within the first 12 months of diagnosis was independently associated with a 40% reduction in the composite outcome of death or transplantation (hazard ratio 0.60, 95% CI 0.40 to 0.91, P=0.016). [6] The registry included infants as young as 1 month. Lisinopril was the most frequently used ACE inhibitor (44% of ACE inhibitor prescriptions in the registry), supporting its specific applicability.

Contraindications and Special Populations

Absolute Contraindications

• History of ACE inhibitor-induced angioedema
• Concomitant use of sacubitril/valsartan (risk of angioedema; 36-hour washout required)
• Pregnancy at any stage (Category D/X; teratogenic and fetotoxic)
• Known bilateral renal artery stenosis or stenosis of a solitary functioning kidney
• Concomitant use of aliskiren in children with diabetes or eGFR <60 mL/min/1.73 m² [1][14]

Neonates and Infants Under 6 Months

Neonatal use carries particular risk. Oliguria and reversible or irreversible renal failure have been reported in neonates exposed to ACE inhibitors in utero, but postnatal exposure is also associated with significant hypotension in premature infants whose renin-angiotensin systems may be tonically active for blood pressure maintenance. [18] A case series from Cincinnati Children's (N=12 neonates receiving enalaprilat or oral enalapril for heart failure) documented symptomatic hypotension in 5 of 12 patients, underscoring the need for intensive hemodynamic monitoring in this age group. [18] Lisinopril is the oral analogue and shares this risk profile.

Children with Single Kidney or Transplant

Renal transplant recipients receive calcineurin inhibitors that themselves raise potassium and creatinine. Adding lisinopril requires particular caution, with baseline and follow-up electrolytes and creatinine checked within 5 to 7 days of initiation. [17]

Practical Prescribing: A Decision Framework

When a clinician considers lisinopril for a child under 12 in an off-label context, the following sequence applies:

1. Confirm the indication: Is there proteinuria above 1 g/day, confirmed DCM, post-surgical hypertension, or another evidence-supported rationale?
2. Check renal function: Obtain baseline creatinine and eGFR. If eGFR is <30 mL/min/1.73 m², start at half the standard weight-based dose.
3. Assess potassium: Baseline potassium above 5.0 mEq/L is a relative contraindication requiring correction before starting.
4. Choose formulation: Children under 6 or unable to swallow tablets need a compounded 1 mg/mL suspension.
5. Start low: 0.07 mg/kg/day, maximum 5 mg first dose.
6. Monitor at 1 to 2 weeks: Recheck creatinine and potassium. A creatinine rise <30% from baseline is acceptable and expected.
7. Titrate every 2 to 4 weeks: Target the lowest dose that achieves blood pressure goal or maximum proteinuria reduction.
8. Document off-label status: Note the indication, evidence base, and shared decision-making discussion in the medical record.

The National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents concluded: "Angiotensin-converting enzyme inhibitors are preferred antihypertensive agents in children with chronic kidney disease, diabetes, or proteinuria because of their renal-protective effects beyond blood pressure control." [10]

Drug Interactions Relevant to Pediatric Patients

Several interactions carry particular relevance in children with complex medical histories:

• NSAIDs: Reduce the antihypertensive and antiproteinuric effect of lisinopril and increase the risk of AKI, particularly in volume-depleted children. Ibuprofen use is common in this age group and should be minimized. [8]
• Potassium-sparing diuretics (spironolactone, amiloride): Additive hyperkalemia risk. Monitor potassium within 1 week of any change in either drug. [9]
• Loop diuretics: May exacerbate first-dose hypotension. Diuretic dose reduction before lisinopril initiation is often prudent. [14]
• Trimethoprim: Blocks tubular secretion of potassium similarly to amiloride. Children with recurrent UTIs on prophylactic TMP-SMX and lisinopril require more frequent potassium monitoring. [9]
• mTOR inhibitors (sirolimus, everolimus): Used in transplant recipients; co-administration with ACE inhibitors increases angioedema risk substantially. [17]

Shared Decision-Making and Parental Counseling

Off-label prescribing in children requires explicit discussion with parents or guardians. Clinicians should explain:

• The FDA approval status and why the drug is being used outside that label
• The specific evidence supporting use (trial data, guideline recommendations)
• The monitoring plan, including blood test frequency
• Signs requiring urgent evaluation: facial or tongue swelling (angioedema), decreased urine output, dizziness on standing, or persistent dry cough
• The importance of avoiding pregnancy in adolescent girls who may be approaching puberty [10][14]

Documenting this conversation in the chart, with parental acknowledgment, is both ethically appropriate and medicolegally protective.